Chief Medical Officer at Nuvation Bio (NUVB) awarded 748,130 stock options

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that its Chief Medical Officer, Dongfang Liu, received a grant of stock options covering 748,130 shares of common stock. The award is classified as a grant or other acquisition rather than an open-market purchase.

According to the terms, the option vests as to 25% of the underlying shares on the one-year anniversary of February 27, 2026, with the remaining portion vesting in equal monthly installments over the following 36 months. Vesting is conditioned on Dr. Liu’s continuous service with the company on each applicable vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Liu Dongfang

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Liu Dongfang

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(1)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvation Bio (NUVB) report for Dongfang Liu?

Nuvation Bio reported a stock option grant to Chief Medical Officer Dongfang Liu covering 748,130 shares. The award is a compensatory grant classified as an acquisition, not an open-market buy or sell transaction, and will vest over several years subject to continued service.

How many Nuvation Bio (NUVB) shares are covered by Dongfang Liu’s new option grant?

The new stock option grant to Chief Medical Officer Dongfang Liu covers 748,130 shares of Nuvation Bio common stock. This entire amount was reported as beneficially owned following the transaction, reflecting the full size of the compensatory equity award granted on the reported date.

What is the vesting schedule for Dongfang Liu’s Nuvation Bio (NUVB) stock options?

The option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months. Each vesting installment requires Dongfang Liu to remain in continuous service with Nuvation Bio on the applicable vesting date to receive the corresponding portion.

Is Dongfang Liu’s Nuvation Bio (NUVB) Form 4 transaction a purchase or a grant?

The Form 4 transaction is a grant, categorized as a grant, award, or other acquisition. It represents a compensatory stock option award to Chief Medical Officer Dongfang Liu, not an open-market purchase or sale of Nuvation Bio shares on a securities exchange.

What role does Dongfang Liu hold at Nuvation Bio (NUVB) in this Form 4 filing?

In this Form 4, Dongfang Liu is identified as an officer of Nuvation Bio, serving as Chief Medical Officer. The reported transaction reflects an equity incentive award associated with this executive role and is held directly, according to the ownership information in the filing.

Are Dongfang Liu’s Nuvation Bio (NUVB) stock options subject to service conditions?

Yes, the stock options are subject to continuous service conditions. Vesting of both the initial 25% one year after February 27, 2026, and the subsequent monthly installments over 36 months requires Dongfang Liu to remain employed or in continuous service with Nuvation Bio.